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We report a case of a patient undergoing hemodialysis who developed a wound infection and subsequently
bacteremia with a strain of vancomycin-resistant enterococcus identified as Enterococcus gallinarum. He had
been receiving vancomycin prophylaxis before developing these infections. Both isolates were susceptible to
ampicillin, rifampin, teicoplanin, and daptomycin (LY146032).
There are approximately 80,000 people receiving hemodi-
alysis in the United States. Over the past several years, it
has become common practice to prophylactically administer
vancomycin to these patients. In many respects, vancomy-
cin is ideally suited to this purpose, since skin flora, com-
posed primarily of gram-positive bacteria, commonly infect
these patients and vancomycin resistance in these organisms
has only rarely been reported (9, 15). In addition, the drug
may be given weekly during hemodialysis. Emerging resis-
tance, however, is always a potential problem with the
administration of prophylactic antibiotics. We report the first
case of bacteremia with a vancomycin-resistant entero-
coccus recovered in the United States in a hemodialysis
patient receiving prophylactic vancomycin. Susceptibilities
to several newly developed antibiotics are also reported.
Case report. A 67-year-old man was admitted to the North
Carolina Memorial Hospital on 6 September 1986 for evalu-
ation of fever and swelling over his left femoral hemodialysis
graft. Seventeen months before admission, the patient began
hemodialysis. At that time, vancomycin (1 g intravenously
[i.v.] each week) was administered. Vancomycin levels in
serum between 14 and 21 ,ug/ml were reported on several
occasions.
During the next year, his course was marked by repeated
episodes of graft failure due to thrombus formation. On 12
June 1986, a left femoral graft was placed. One month later,
swelling was noted around the graft site and an ultrasound of
the area revealed several cystic collections.
Cultures of spontaneous drainage from one of these col-
lections grew Escherichia coli, Klebsiella pneumoniae, and
an Enterococcus sp. Broth macrodilution testing of the
enterococcal isolate revealed that the vancomycin MIC was
16 ,ug/ml. The patient was maintained on his weekly vanco-
mycin, and on 6 September he returned to the North
Carolina Memorial Hospital after 48 h of fever and chills. His
oral temperature was 100.2°F (ca. 37.9°C), and his physical
exam was remarkable for a foul-smelling exudate from a
wound over his graft site.
Enterococci were recovered from three of four blood
cultures taken upon admission. Microdilution MIC testing
(8) revealed that for this isolate, penicillin and ampicillin
MICs were 1.0 ,ug/ml and the vancomycin MIC was 16.0
,tg/ml. The vancomycin MIC was confirmed by broth macro-
dilution MIC testing (8). Kill-curve studies (11) with mea-
sured levels in serum of vancomycin (20 ,ug/ml) and genta-
micin (5 ,ug/ml) demonstrated synergy for the blood isolate
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(data not shown). Broth macrodilution MICs of other agents
with antistreptococcal activity are reported in Tables 1 and
2.
The bacteremia of the patient was treated with 2 g of
piperacillin i.v. every 8 h and 150 mg of gentamicin i.v. after
each dialysis. His temperature rapidly returned to normal,
and he was sent home to complete a 4-week course of
vancomycin and gentamicin. The blood and wound-drainage
isolates were sent to the Centers for Disease Control in
Atlanta, Ga., for identification and confirmation of the
vancomycin MIC findings. The blood and wound isolates
were identified as Enterococcus gallinarum. The MIC of
vancomycin for both isolates was 16 ,ug/ml.
The patient did well until 15 December 1986, when he
again experienced rigors and fever. A golf-ball-sized mass
was palpable in his left groin, and when it was aspirated, an
E. gallinarum isolate for which the vancomycin MIC was 16
,ug/ml was recovered. Four of four blood cultures, however,
grew Pseudomonas aeruginosa, and his graft was removed.
He did well after a 4-week course of ceftazidime and
tobramycin.
Discussion. Vancomycin resistance in gram-positive organ-
isms is highly unusual. It had been reported in only two
genera of gram-positive organisms, Leuconostoc (12) and
Lactobacillus (2, 17). The enterococci, which include the
species E. faecalis, E. durans, E. faecium, and E. avium,
have been reported to be susceptible to vancomycin, with
MICs in the range of 0.5 to 8.0 ,ug/ml (1, 3, 5, 7, 10, 14).
Recently Uttley et al. (16) have isolated eight vancomycin-
resistant Enterococcus strains from the blood of patients
with end-stage renal disease. There have been no previous
reports of E. gallinarum of human origin. For the blood and
wound isolates of enterococci reported here, the vancomy-
cin MICs were 16 ,ug/ml.
The E. gallinarum isolates could be clearly differentiated
from both Leuconostoc sp. and Lactobacillus sp. The MICs
of vancomycin for both isolates were relatively low com-
pared with those reported for Leuconostoc sp. (MIC range,
500 to >2,000 ,ug/ml). In addition, both Enterococcus iso-
lates were able to split arginine and acidify litmus milk,
characteristics which are not found in Leuconostoc sp. (6).
Also, the E. gallinarum isolates failed to produce gas in
Lactobacillus MRS broth, and Leuconostoc sp. produces
gas in this broth (6). For certain lactobacilli, vancomycin
MICs may be similar to those for the isolates described here.
However, the Gram stain, colonial morphology, and defini-
tive physiologic characteristics unique to E. gallinarum
clearly indicate that these isolates were not lactobacilli.
It was clear that the blood and wound isolates were the
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Fusidic acid 2/>128 4/>128
Bacitracin' 32/128 16/64
a MBC was defined as 99.9%o killing of the starting inoculum, which was
between 1.2 x 105 and 1.4 x 105 CFU/ml.
b Values for bacitracin are given in units per milliliter.
same organism. Both were clearly enterococci: they were
typed in serogroup D antiserum, were catalase negative and
alpha-hemolytic, hydrolyzed bile-esculin, and grew in the
presence of 6.5% NaCI and at 10 and 45°C. Biochemically,
the isolates differed from other Enterococcus species by
their motility and nonpigmentation. Only two species of
enterococcus are motile, E. gallinarum and E. casseliflavus.
E. casseliflavus is pigmented (yellow), but E. gallinarum is
not (4). The E. gallinarum isolate had two typical physio-
logic characteristics of the type strain for this species (4).
The antimicrobial susceptibilities of the two isolates were
similar (Table 1). For both isolates described here, ampicillin
MICs were as expected for enterococci, but surprisingly,
both were resistant to vancomycin. We do not know whether
other E. gallinarum isolates have the same antimicrobial
susceptibilities as these isolates. The most active agents by
weight were rifampin, daptomycin (LY146032; an investiga-
tional lipopeptide made by Eli Lilly & Co., Indianapolis,
Ind.), and teicoplanin. We have previously reported (13) that
teicoplanin had activity superior to that of daptomycin
against E. faecalis. For the two E. gallinarum isolates
described here, the MICs of those two agents were similar.
Daptomycin, however, had bactericidal activity superior to
that of teicoplanin (Tables 1 and 2). Variations in inoculum
size did not significantly affect the activities of vancomycin,
daptomycin, or teicoplanin (Table 2).
The patient was treated unsuccessfully with vancomycin
and gentamicin, despite in vitro testing which predicted
synergy of these two agents; ultimately, graft removal was
TABLE 2. Effect of inoculum size on antimicrobial activity
of vancomycin, teicoplanin, and daptomycin
against two enterococcal isolates
Inoculum MIC/MBCa (,ug/ml) for:Drug(CFU/ml) Blood isolate Wound isolate
Vancomycin 102 16/16 16/>128
104 16/>128 16/>128
106 16/>128 16/>128
Teicoplanin 102 1/8 0.5/16
104 1/16 0.5/128
106 1/32 2/>128
Daptomycin 102 2/8 2/2
104 2/8 2/8
106 4/8 2/8
a MBCs for the 102-CFU/ml inoculum were defined as the lowest drug
concentration allowing no growth on the subculture.
required. It is likely that the infection of this graft with a
vancomycin-resistant enterococcus contributed to the fail-
ure of the graft. In this case, long-term vancomycin prophy-
laxis appears to have provided the selective pressure to
produce an organism which was susceptible to penicillin but
resistant to vancomycin. This lends credence to the conten-
tion that vancomycin prophylaxis leads to colonization and
infection with vancomycin-resistant organisms. An addi-
tional case report has documented a vancomycin-resistant
Staphylococcus haemolyticus strain which was isolated from
the peritoneal dialysis fluid of a patient with end-stage renal
disease and peritonitis (13). That patient had received sev-
eral courses of vancomycin, both as therapy and as prophy-
laxis. MICs for his isolates gradually increased over several
months of vancomycin therapy. Although widespread van-
comycin resistance among gram-positive bacteria has not
been reported, populations on long-term vancomycin-sup-
pressive therapy, like those receiving hemodialysis, may
prove to be a reservoir for these difficult-to-treat infections.
We thank Jonathan Serody for referring this patient. We also
thank Clyde Thornsberry of the Centers for Disease Control,
Atlanta, Ga., for susceptibility testing confirmation. Finally, we
thank Kimberley Jack-Wait for performing the in vitro susceptibility
studies and Karen Alston and Cindy Biles for help in the manuscript
preparation.
LITERATURE CITED
1. Barry, A. L., C. Thornsberry, and R. N. Jones. 1986. Evaluation
of teicoplanin and vancomycin disk susceptibility tests. J. Clin.
Microbiol. 23:100-103.
2. Bayer, A. S., A. W. Chow, D. Betts, and L. B. Guze. 1978.
Lactobacillemia-report of nine cases. Am. J. Med. 64:809-813.
3. Chaudrasekar, P. H., S. Price, and D. P. Levine. 1985. In-vitro
evaluation of cefpirome (HR 810), teicoplanin and four other
antimicrobials against enterococci. J. Antimicrob. Chemother.
16:179-182.
4. Collins, M. D., D. Jones, J. A. E. Farrow, R. Kilpper-Balz, and
K. H. Schleifer. 1984. Enterococcus avium nom. rev., comb.
nov.; E. casseliflavus nom. rev., comb. nov.; E. durans nom.
rev., comb. nov.; E. gallinarum comb. nov.; and E. malodo-
ratus sp. nov. Int. J. Syst. Bacteriol. 34:220-223.
5. Eliopoulos, G. M., S. Willey, E. Reiszner, P. G. Spitzer, G.
Caputo, and R. C. Moellering, Jr. 1986. In vitro and in vivo
activity of LY 146032, a new cyclic lipopeptide antibiotic.
Antimicrob. Agents Chemother. 30:532-535.
6. Garvie, E. I. 1984. Separation of species of the genus Leuco-
nostoc and differentiation of the Leuconostocs from other lactic
acid bacteria, p. 147-178. In T. Bergan (ed.), Methods in
microbiology, vol. 16. Academic Press, Inc., New York.
7. Hodinka, R. L., K. Jack-Wait, N. Wannamaker, T. P. Walden,
and P. G. Gilligan. 1987. Comparative in vitro activity of LY
146032 (Deptomycin), a new lipopeptide antimicrobial. Eur. J.
Clin. Microbiol. 6:100-103.
8. Jones, R. N., A. L. Barry, T. L. Gavan, and J. A. Washington Il.
1985. Susceptibility tests: microdilution and macrodilution
broth procedures, p. 972-977. In E. H. Lennette, A. Balows,
W. J. Hausler, Jr., and H. J. Shadomy (ed.), Manual of clinical
microbiology, 4th ed. American Society for Microbiology,
Washington, D.C.
9. Kaye, D. 1982. Enterococci: biologic and epidemiologic charac-
teristics and in vitro susceptibility. Arch. Intern. Med. 142:
2006-2007.
10. Kim, M. J., M. Weiser, S. Gottschall, and E. L. Randall. 1987.
Identification of Streptococcus faecalis and Streptococcus fae-
cium and susceptibility studies with newly developed antimicro-
bial agents. J. Clin. Microbiol. 25:787-790.
11. Krogstad, D. J., and R. C. Moellering, Jr. 1986. Antimicrobial
combinations, p. 537-595. In V. Lorian (ed.), Antibiotics in




12. Orberg, P. K., and W. E. Sandine. 1984. Common occurrence of
plasmid DNA and vancomycin resistance in Leuconostoc spp.
Apple. Environ. Microbiol. 48:1129-1133.
13. Schwalbe, R. S., J. I. Stapleton, and P. H. Gilligan. 1987.
Emergence of vancomycin resistance in coagulase-negative
staphylococci. N. Engl. J. Med. 316:927-931.
14. Tofte, R. W., J. Solliday, and K. B. Crossley. 1984. Susceptibil-
ities of enterococci to twelve antibiotics. Antimicrob. Agents
Chemother. 25:532-533.
15. Tuazon, C. V., and H. Miller. 1983. Clinical and microbiologic
aspects of serious infections caused by Staphylococcus epider-
midis. Scand. J. Infect. Dis. 15:347-360.
16. Uttley, A. H. C., C. H. Collins, J. Naidoo, and R. C. George.
1988. Vancomycin-resistant enterococci. Lancet i:57-58.
17. Vescovo, M., L. Morelli, and V. Bottazzi. 1982. Drug resistance
plasmids in Lactobacillus acidophilus and Lactobacillus reuteri.
Apple. Environ. Microbiol. 43:50-56.
1218 NOTES
